Market Cap 2.98B
Revenue (ttm) 7.00M
Net Income (ttm) -274.48M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,921.14%
Debt to Equity Ratio 0.00
Volume 845,800
Avg Vol 1,086,090
Day's Range N/A - N/A
Shares Out 87.67M
Stochastic %K 23%
Beta 0.04
Analysts Strong Sell
Price Target $48.94

Company Profile

IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 2 clinical trials for patients with solid tumor...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 443 6209
Address:
5000 Shoreline Court, Suite 300, South San Francisco, United States
_intergalacticSwings
_intergalacticSwings Dec. 13 at 9:42 PM
0 · Reply
CDMO
CDMO Dec. 13 at 7:48 AM
$IDYA i like these targets
0 · Reply
Quantumup
Quantumup Dec. 12 at 3:29 PM
Citi Opened an 'Upside 90-day Catalyst Watch' on $IDYA, reiterated at a Buy-$64, and said that it likes the share setup into the Phase 2/3 OptimUM-02 trial data, expected in Q1, for metastatic uveal melanoma (mUM). $PFE $MRK $BMY
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 12 at 12:53 AM
Actionable Trade Alert for $IDYA: Market Context: $IDYA is currently trading at $33.79, which is above its 30-day moving average (MA30) of $33.13 and significantly above its 60-day low of $24.95. The RSI of 53.23 indicates a neutral to slightly bullish sentiment, suggesting potential upward momentum. Directional Bias: The stock is positioned favorably above the MA30 and MA50 (31.32), indicating a bullish trend. With the recent high at $37.08, there is room for growth, and the ATR of 1.52 suggests manageable volatility. Trade Plan: - Suggested Entry: $34.00 - Stop Loss: $31.50 (approx. 7.4% below entry) - Take Profit Targets: 1. $36.00 (5.88% gain) 2. $37.00 (8.82% gain) 3. $39.50 (16.88% gain) This plan offers a potential ROI of over 17% at the third target. Monitor price action closely and adjust stop loss as needed. https://privateprofiteers.com
0 · Reply
CH_Expat
CH_Expat Dec. 11 at 8:00 PM
$IDYA It is crazy, reassuring and encouraging at the same time nobody gives a flying f about this stock. Just stunned. But hey, me no complaino. They can embrace their TNXP and AUPH and ALT Buyoutbullshiting in the meantime.
1 · Reply
CH_Expat
CH_Expat Dec. 11 at 7:36 PM
$IDYA https://x.com/jeromeleonard5/status/1999147633755976125 He is by far the most educated public voice speaking about the stock.
0 · Reply
OpenOutcrier
OpenOutcrier Dec. 11 at 1:53 PM
$IDYA (-3.8% pre) IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal M https://ooc.bz/l/87176
0 · Reply
RonIsWrong
RonIsWrong Dec. 11 at 1:00 PM
$IDYA Ideaya Biosciences Completed Its Targeted Full Enrollment of 435 Patients In Phase 2/3 OptimUM-02 Trial of Darovasertib Combined With Pfizer's Crizotinib for HLA*A2-Negative Metastatic Uveal Melanoma; Median Progression-free Survival Data is Expected in Q1 2026
1 · Reply
BillionerOfKing
BillionerOfKing Dec. 11 at 11:56 AM
$IDYA Current Stock Price: $33.69 Contracts to trade: $35 IDYA Dec 19 2025 Call Entry: $2.25 Exit: $3.32 ROI: 48% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
SannieVerraderlijk
SannieVerraderlijk Dec. 11 at 11:55 AM
$IDYA https://x.com/BioStocks/status/1999072000523042938?s=20
0 · Reply
Latest News on IDYA
IDEAYA (IDYA) Q2 Net Loss Improves 27%

Aug 5, 2025, 4:23 PM EDT - 4 months ago

IDEAYA (IDYA) Q2 Net Loss Improves 27%


Ideaya Biosciences: Moving Into ADCs For Solid Tumors

Aug 5, 2025, 8:43 AM EDT - 4 months ago

Ideaya Biosciences: Moving Into ADCs For Solid Tumors


Why Ideaya Biosciences Is Down Despite Many Positives

Apr 2, 2025, 11:12 AM EDT - 9 months ago

Why Ideaya Biosciences Is Down Despite Many Positives


_intergalacticSwings
_intergalacticSwings Dec. 13 at 9:42 PM
0 · Reply
CDMO
CDMO Dec. 13 at 7:48 AM
$IDYA i like these targets
0 · Reply
Quantumup
Quantumup Dec. 12 at 3:29 PM
Citi Opened an 'Upside 90-day Catalyst Watch' on $IDYA, reiterated at a Buy-$64, and said that it likes the share setup into the Phase 2/3 OptimUM-02 trial data, expected in Q1, for metastatic uveal melanoma (mUM). $PFE $MRK $BMY
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 12 at 12:53 AM
Actionable Trade Alert for $IDYA: Market Context: $IDYA is currently trading at $33.79, which is above its 30-day moving average (MA30) of $33.13 and significantly above its 60-day low of $24.95. The RSI of 53.23 indicates a neutral to slightly bullish sentiment, suggesting potential upward momentum. Directional Bias: The stock is positioned favorably above the MA30 and MA50 (31.32), indicating a bullish trend. With the recent high at $37.08, there is room for growth, and the ATR of 1.52 suggests manageable volatility. Trade Plan: - Suggested Entry: $34.00 - Stop Loss: $31.50 (approx. 7.4% below entry) - Take Profit Targets: 1. $36.00 (5.88% gain) 2. $37.00 (8.82% gain) 3. $39.50 (16.88% gain) This plan offers a potential ROI of over 17% at the third target. Monitor price action closely and adjust stop loss as needed. https://privateprofiteers.com
0 · Reply
CH_Expat
CH_Expat Dec. 11 at 8:00 PM
$IDYA It is crazy, reassuring and encouraging at the same time nobody gives a flying f about this stock. Just stunned. But hey, me no complaino. They can embrace their TNXP and AUPH and ALT Buyoutbullshiting in the meantime.
1 · Reply
CH_Expat
CH_Expat Dec. 11 at 7:36 PM
$IDYA https://x.com/jeromeleonard5/status/1999147633755976125 He is by far the most educated public voice speaking about the stock.
0 · Reply
OpenOutcrier
OpenOutcrier Dec. 11 at 1:53 PM
$IDYA (-3.8% pre) IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal M https://ooc.bz/l/87176
0 · Reply
RonIsWrong
RonIsWrong Dec. 11 at 1:00 PM
$IDYA Ideaya Biosciences Completed Its Targeted Full Enrollment of 435 Patients In Phase 2/3 OptimUM-02 Trial of Darovasertib Combined With Pfizer's Crizotinib for HLA*A2-Negative Metastatic Uveal Melanoma; Median Progression-free Survival Data is Expected in Q1 2026
1 · Reply
BillionerOfKing
BillionerOfKing Dec. 11 at 11:56 AM
$IDYA Current Stock Price: $33.69 Contracts to trade: $35 IDYA Dec 19 2025 Call Entry: $2.25 Exit: $3.32 ROI: 48% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
SannieVerraderlijk
SannieVerraderlijk Dec. 11 at 11:55 AM
$IDYA https://x.com/BioStocks/status/1999072000523042938?s=20
0 · Reply
SimpleWinningSetups
SimpleWinningSetups Dec. 11 at 4:25 AM
📈 Simple Winning Setups – Simple Winning Setup Detected Ticker: $CMBM | Timeframe: 6M / 1D Market Cap: $54.79M • Pattern score: 0.82 • Current price: $1.940 • Peak (window): $3.750 • Trough (post-spike): $1.590 • Pullback: ~57.6% from peak • Move off lows: ~51.7% of peak Stock Plan (educational only) • Entry zone: $1.882 – $1.979 • Scalp target: $2.095 → Est. ROI: ~8.0% • Swing target: $3.000 → Est. ROI: ~54.6% • Protective stop: $1.649 → Risk: ~15.0% below current Options Idea (real chain data only) • Type: Call | Example Exp: 2026-01-16 • Example Strike: ~$2.000 (≈5% OTM) • Example Premium (entry): ~$0.425 → Exit target: ~$0.744 (≈+75% vs entry) → Protective stop: ~$0.255 (≈-40% vs entry) • Structure: single swing call, risk defined by your stock-level stop. This is an automated pattern alert from Simple Winning Setups. For education & research only – not financial advice. https://www.simplewinningsetups Trending Ticker Watch: $IDYA
0 · Reply
CH_Expat
CH_Expat Dec. 10 at 6:52 PM
$IDYA Low volume selloff days short before crucial data readouts. Unseen before.
0 · Reply
briefingcom
briefingcom Dec. 10 at 1:08 PM
$IDYA: IDEAYA Biosciences files IND to advance first-in-class KAT6/7 oncology program https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20251210060523IDYA&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
0 · Reply
CH_Expat
CH_Expat Dec. 10 at 11:47 AM
$IDYA Which way will they go? Become ALNY or become BPMC?
1 · Reply
RonIsWrong
RonIsWrong Dec. 10 at 11:36 AM
$IDYA IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers Phase 1 dose escalation trial of monotherapy IDE574 expected to begin in 1Q 2026 Targeting to present preclinical data detailing pharmacologic profile and evidence of anti-tumor activity in solid tumor models at a medical conference in 1H 2026
0 · Reply
RonIsWrong
RonIsWrong Dec. 10 at 5:26 AM
$IDYA short interest down a little more, lowest of the year.
1 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 4:56 AM
Actionable Trade Alert for $IDYA: Market Context: $IDYA is currently trading at $34.08, showing a stable price action with an RSI of 51.89, indicating neutral momentum. The stock is above its 30-day moving average (MA30) of $33.06 and significantly above its 50-day moving average (MA50) of $31.06, suggesting a bullish trend. Directional Bias: The price is closer to the 60-day high of $37.08, indicating potential upward momentum. The ATR of 1.51 suggests moderate volatility, allowing for strategic entry and exit points. Trade Plan: - Suggested Entry: $34.10 - Stop Loss: $32.50 (approximately 4.68% below entry) - Take Profit Targets: - Target 1: $36.00 (17.5% ROI) - Target 2: $37.00 (24.5% ROI) - Target 3: $39.00 (43.2% ROI) This plan provides a solid risk-reward ratio with a potential ROI of over 17% on the third target. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
SimpleWinningSetups
SimpleWinningSetups Dec. 9 at 9:07 PM
Hedge Alert Live - Protect Your Portfolio Contract: $IDYA $30.00 Put · DEC 19, 2025 Exp Entry Price: $0.20 - $1.00 Exit Price Target: $0.32 Profit Margin: +61% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 9 at 12:44 AM
Actionable Trade Alert for $IDYA: Market Context: $IDYA is currently trading at $35.59, showing strong momentum as indicated by an RSI of 63.04, suggesting it is nearing overbought territory but still has room for growth. The stock is above its 30-day (MA30) and 50-day (MA50) moving averages, indicating a bullish trend. Directional Bias: The bullish trend is supported by the proximity to the 60-day high of $37.08. The upward momentum suggests potential for further gains, especially considering the recent price action. Trade Plan: - Suggested Entry: $35.60 - Stop Loss: $34.00 (1.46 ATR below the entry) - Take Profit Targets: 1. Target 1: $37.00 (4% gain) 2. Target 2: $38.00 (6% gain) 3. Target 3: $41.75 (17.5% gain) With a clear upward trajectory and the potential for significant returns, this trade presents a favorable risk-reward scenario. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
CDMO
CDMO Dec. 7 at 11:07 PM
$IDYA interesting table from TD Cowen. IDYAs mentioned estimated up-/downside is (+20-30%/-30-50)
0 · Reply
CH_Expat
CH_Expat Dec. 6 at 8:57 AM
$IDYA Chance to add in case of a massive overreaction!
1 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 3:43 AM
$IDYA is currently trading at $36.01, with an RSI of 71.53 indicating overbought conditions. The 30-day moving average (MA30) is at $32.55, and the 50-day moving average (MA50) is at $30.55, suggesting strong bullish momentum as the price is above both MAs. The recent 60-day high is $36.61, which could act as a resistance level, while the low is $24.24, indicating a significant range for potential price movement. Action Plan: - Suggested Entry: $36.01 - Stop Loss: $34.00 (approx. 5.6% below entry) - Take Profit Targets: 1. $37.50 (4.1% gain) 2. $39.00 (8.3% gain) 3. $42.00 (16.7% gain) Target 3 offers a potential ROI of 16.7%, just shy of the 17% mark, but with the current bullish trend and proximity to the 60D high, it remains a viable target. Monitor RSI for potential reversals. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply